Tnf-alpha binding proteins
AssigneeAbbott Laboratories
InventorsChung-ming HSIEH, Carrie L. GOOGREAU, Sahana BOSE, Achim MOELLER, Tariq GHAYUR
Life of this patent
Estimating the term…
Abstract
TNF-α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind TNF-α are provided. Binding proteins have high affinity for TNF-α and neutralize TNF-α activity. A binding protein can be a full-length antibody or a TNF-α-binding portion thereof. Methods of making and methods of using the binding proteins are also described. The TNF-α binding proteins are useful for detecting TNF-α and for inhibiting TNF-α activity, including in a human subject suffering from a disease or disorder in which TNF-α activity is detrimental.
Claims55
An antibody, or antigen binding portion thereof comprising SEQ ID NO:
- 31, SEQ ID NO:
- 32, SEQ ID NO:
- 33, SEQ ID NO:
- 34, SEQ ID NO:
- 35, SEQ ID NO:
- 36, SEQ ID NO:
- 37, SEQ ID NO:
- 38, SEQ ID NO:
- 39;
- SEQ ID NO:
- 40;
- SEQ ID NO:
- 41;
- SEQ ID NO:
- 42;
- SEQ ID NO:
- 43;
- SEQ ID NO:
- 44;
- SEQ ID NO:
- 45;
- or SEQ ID NO:
- 46.
An antibody, or antigen binding portion thereof, capable of binding TNF-α comprising at least one CDR comprising residues 31-35 of SEQ ID NO:31 (CDR-H1), residues 50-66 of SEQ ID NO:31 (CDR-H2), residues 99-113 of SEQ ID NO:31 (CDR-H3), residues 24-34 of SEQ ID NO:32 (CDR-L1), residues 50-56 of SEQ ID NO:32 (CDR-L2), or residues 89-97 of SEQ ID NO:32 (CDR-L3).
The host cell of 32, wherein said host cell is a eukaryotic cell.
The method of claim 46, wherein the disorder is Crohn's disease, plaque psoriasis, rheumatoid arthritis, psoratic arthritis, osteoarthritis, juvenile idiopathic arthritis, multiple sclerosis, systemic lupus erythematosus, ankylosing spondylitis, insulin-dependent diabetes mellitus, autoimmune diabetes, allergy, and autoimmune uveitis.
Dependencies are inferred from the claim text.